MHC class II molecules display antigenic peptides on cell surfaces for recognition by CD4(+) T cells. Proteolysis is required in this process both for degradation of invariant chain (Ii) from class II-Ii complexes to allow subsequent binding of peptides, and for generation of the antigenic peptides. The cysteine endoprotease, cathepsin S, mediates Ii degradation in human and mouse antigen-presenting cells. Studies described here examine the functional significance of cathepsin S inhibition on antigen presentation and immunity. Specific inhibition of cathepsin S in A20 cells markedly impaired presentation of an ovalbumin epitope by interfering with class II-peptide binding, not by obstructing generation of the antigen. Administration of a cathepsin S inhibitor to mice in vivo selectively inhibited activity of cathepsin S in splenocytes, resulting in accumulation of a class II-associated Ii breakdown product, attenuation of class II-peptide complex formation, and inhibition of antigen presentation. Mice treated with inhibitor had an attenuated antibody response when immunized with ovalbumin but not the T cell-independent antigen TNP-Ficoll. In a mouse model of pulmonary hypersensitivity, treatment with the inhibitor also abrogated a rise in IgE titers and profoundly blocked eosinophilic infiltration in the lung. Thus, inhibition of cathepsin S in vivo alters Ii processing, antigen presentation, and immunity. These data identify selective inhibition of cysteine proteases as a potential therapeutic strategy for asthma and autoimmune disease processes.
R J Riese, R N Mitchell, J A Villadangos, G P Shi, J T Palmer, E R Karp, G T De Sanctis, H L Ploegh, H A Chapman
Title and authors | Publication | Year |
---|---|---|
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation
N Fissolo, M Kraus, M Reich, M Ayturan, H Overkleeft, C Driessen, R Weissert |
European Journal of Immunology | 2008 |
Methamphetamine inhibits antigen processing, presentation, and phagocytosis
Z Tallóczy, J Martinez, D Joset, Y Ray, A Gácser, S Toussi, N Mizushima, JD Nosanchuk, J Nosanchuk, H Goldstein, J Loike, D Sulzer, L Santambrogio |
PLoS pathogens | 2008 |
Advances in multiple Sclerosis and Experimental Demyelinating Diseases
M Rodriguez |
2008 | |
Inhibition of Invariant Chain Processing, Antigen-Induced Proliferative Responses, and the Development of Collagen-Induced Arthritis and Experimental Autoimmune Encephalomyelitis by a Small Molecule Cysteine Protease Inhibitor
PL Podolin, BJ Bolognese, DC Carpenter, TG Davis, RA Johanson, JH Fox, E Long, X Dong, RW Marquis, SM LoCastro, GJ Terfloth, E Kurali, JJ Peterson, BR Smith, MS McQueney, DS Yamashita, EA Capper-Spudich |
Journal of immunology (Baltimore, Md. : 1950) | 2008 |
Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR
BA Cobb, DL Kasper |
Glycobiology | 2008 |
Clinical Immunology
DB Kuhns |
Clinical Immunology | 2008 |
Cathepsin K-Dependent Toll-Like Receptor 9 Signaling Revealed in Experimental Arthritis
M Asagiri, T Hirai, T Kunigami, S Kamano, HJ Gober, K Okamoto, K Nishikawa, E Latz, DT Golenbock, K Aoki, K Ohya, Y Imai, Y Morishita, K Miyazono, S Kato, P Saftig, H Takayanagi |
Science | 2008 |
Common functional polymorphisms in the cathepsin S promoter in Japanese subjects: Possible contribution to pulmonary emphysema
N MINEMATSU, H NAKAMURA, M FURUUCHI, T NAKAJIMA, S TAKAHASHI, S TSUJIMURA, H TATENO, A ISHIZAKA |
Respirology | 2008 |
Cysteine cathepsin S as an immunomodulatory target: present and future trends
S Gupta, RK Singh, S Dastidar, A Ray |
Expert Opinion on Therapeutic Targets | 2008 |
Upregulation of cathepsin S in the aging and pathological nervous system of mice
W Wendt, H Lübbert, CC Stichel |
Brain Research | 2008 |
Molecular cloning, sequencing and characterization of channel catfish (Ictalurus punctatus, Rafinesque 1818) cathepsin S gene
HY Yeh, PH Klesius |
Veterinary Immunology and Immunopathology | 2008 |
Roles of a metastasis-associated molecule, RTVP-1, in cancer immunosurveillance
S Junwen, C Wenjun, Y Guang, H Jianguo, M Liye, Z Hongwei, T Xiaojie, H Xiang, TC Thompson, C Guangwen |
Journal of Medical Colleges of PLA | 2008 |
Cysteine cathepsin proteases as pharmacological targets in cancer
C Palermo, JA Joyce |
Trends in Pharmacological Sciences | 2008 |
Regulation of Dendritic Cell Migration by CD74, the MHC Class II-Associated Invariant Chain
G Faure-Andre, P Vargas, MI Yuseff, M Heuze, J Diaz, D Lankar, V Steri, J Manry, S Hugues, F Vascotto, J Boulanger, G Raposo, MR Bono, M Rosemblatt, M Piel, AM Lennon-Dumenil |
Science | 2008 |
2-D DIGE analyses of enriched secretory lysosomes reveal heterogeneous profiles of functionally relevant proteins in leukemic and activated human NK cells
H Schmidt, C Gelhaus, M Nebendahl, M Lettau, C Watzl, D Kabelitz, M Leippe, O Janssen |
PROTEOMICS | 2008 |
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2
O Irie, T Kosaka, M Kishida, J Sakaki, K Masuya, K Konishi, F Yokokawa, T Ehara, A Iwasaki, Y Iwaki, Y Hitomi, A Toyao, H Gunji, N Teno, G Iwasaki, H Hirao, T Kanazawa, K Tanabe, PC Hiestand, M Malcangio, AJ Fox, SJ Bevan, M Yaqoob, AJ Culshaw, TW Hart, A Hallett |
Bioorganic & Medicinal Chemistry Letters | 2008 |